Cargando…
A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6
The triple-negative breast cancer (TNBC) subtype is the most aggressive type of breast cancer with a low survival prognosis and high recurrence rate. There is currently no effective treatment to improve it. In this work, we explored the effect of a synthetic compound named WXJ-103 on several aspects...
Autores principales: | Ji, Jing, Zhang, Zhen, He, Xingbei, Pan, Gang, Li, Guanchu, Lv, Jinyu, Xu, Yuxin, Xie, Mengru, Feng, Jing, Wang, Weiling, Liu, Bin, Ma, Jinming, Wang, Xiujun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344442/ https://www.ncbi.nlm.nih.gov/pubmed/36729405 http://dx.doi.org/10.1097/CAD.0000000000001475 |
Ejemplares similares
-
WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6
por: Ji, Jing, et al.
Publicado: (2023) -
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020) -
Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019) -
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023) -
Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)